CLEARPOINT NEURO INC.
13.42
07-November-24 15:59:54
15 minutes delayed
Stocks
+0.04
+0.30%
Today's range
13.15 - 13.86
ISIN
N/A
Source
NASDAQ
-
ClearPoint Neuro Announces First EU MDR Certification Success and Approval to Ship Product to Europe
22 Jan 2024 16:05:00 By Nasdaq GlobeNewswire
-
ClearPoint Neuro Announces FDA Clearance for SmartFrame OR™ Stereotactic System
16 Jan 2024 08:00:00 By Nasdaq GlobeNewswire
-
08 Jan 2024 16:05:00 By Nasdaq GlobeNewswire
-
ClearPoint Neuro Reports Third Quarter 2023 Results
09 Nov 2023 16:05:01 By Nasdaq GlobeNewswire
-
ClearPoint Neuro to Announce Third Quarter 2023 Results November 9, 2023
26 Oct 2023 16:05:00 By Nasdaq GlobeNewswire
-
ClearPoint Neuro Reports Second Quarter 2023 Results
08 Aug 2023 16:05:01 By Nasdaq GlobeNewswire
-
ClearPoint Neuro to Announce Second Quarter 2023 Results August 8, 2023
25 Jul 2023 16:05:00 By Nasdaq GlobeNewswire
-
ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery
24 May 2023 09:25:00 By Nasdaq GlobeNewswire
-
ClearPoint Neuro to Present at the B. Riley Securities 2023 Institutional Investor Conference
18 May 2023 16:01:00 By Nasdaq GlobeNewswire
-
ClearPoint Neuro Reports First Quarter 2023 Results
11 May 2023 16:05:01 By Nasdaq GlobeNewswire
-
10 May 2023 16:05:00 By Nasdaq GlobeNewswire
-
ClearPoint Neuro to Announce First Quarter 2023 Results May 11, 2023
28 Apr 2023 16:42:12 By Nasdaq GlobeNewswire
-
20 Apr 2023 16:05:00 By Nasdaq GlobeNewswire
-
18 Apr 2023 16:05:00 By Nasdaq GlobeNewswire
-
ClearPoint Neuro Announces ANVISA Approval of Neuro Navigation Portfolio in Brazil
13 Apr 2023 16:05:00 By Nasdaq GlobeNewswire
-
11 Apr 2023 16:05:00 By Nasdaq GlobeNewswire
-
28 Mar 2023 16:05:00 By Nasdaq GlobeNewswire
-
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2022 Results
01 Mar 2023 16:05:01 By Nasdaq GlobeNewswire
-
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2022 Revenue Results March 1, 2023
15 Feb 2023 16:05:00 By Nasdaq GlobeNewswire
-
11 Jan 2023 08:00:00 By Nasdaq GlobeNewswire